Molecular monitoring of minimal residual disease in acute myeloblastic leukemia with t(8;21) by RT-PCR

Leukemia and Lymphoma

Volumn 31, Issue 1-2, 1998, Pages 115-120

  Tobal, Khalid ^a   Liu Yin, John A ^a  

^a MANCHESTER ROYAL INFIRMARY   (United Kingdom)

Author keywords

Acute myeloblastic leukemia; Minimal residual disease; Molecular monitoring; RT PCR; t(8; 21)

Indexed keywords

ACUTE MYELOBLASTIC LEUKEMIA; CHROMOSOME 21Q; CHROMOSOME 8Q; CHROMOSOME TRANSLOCATION; MINIMAL RESIDUAL DISEASE; MONITORING; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; REVIEW;

EID: 0031677775     PISSN: 10428194     EISSN: None     Source Type: Journal    
DOI: 10.3109/10428199809057591     Document Type: Review

References (39)

1. Bennett, J. M., Catovsky, D., Daniel, M. T., Flandrin, G., Galton, D. A. G., Gralnick, H. R. and Sultan, C. (1985). Proposed revised criteria for the classification of the acute myeloid leukemia: A report of the French-American-British Co-operative Group. Ann. Intern. Med., 103, 620-625.
2. Rowley, J. D. (1973). Identification of a translocation with quinacrine fluorescence in a patient with acute myeloid leukemia. Ann. Genet., 16, 109-112.
3. Raimondi, S. C., Kalwinsky, D. K., Hayashi, Y., Behm, F. G., Mirro, J. Jr. and Williams, D. L. (1989). Cytogenetics of childhood acute nonlymphocytic leukemia. Cancer Genet. Cytogenet., 40, 13-27.
4. Rowley, J. D. (1990). Recurring chromosome abnormalities in leukemia and lymphoma. Semin. Hematol., 27, 122-136.
5. Pedersen-Bjergaard, J. and Rowley, J. D. (1994). The balanced and unbalanced chromosome aberrations of acute myeloid leukemia may develop in different ways and may contribute differently to malignant transformation. Blood, 83, 2780-2786.
6. Yamasaki, H., Era, T., Asou, N., Sanada, I., Matutes, E., Yamaguchi, K. and Takatsuki, K. (1995). High degree of myeloid differentiation and granulocytosis is associated with t(8;21) smoldering leukemia. Leukemia, 9, 1147-1153.
7. Swirsky, D. M., Li, Y. S., Matthews, J. G., Flemans, R. J., Rees, J. K. and Hayhoe, F. G. (1984). 8;21 translocation in acute granulocytic leukaemia: cytological, cytochemical and clinical features. Br. J. Haematol., 56, 199-213.
8. Wheatly, K., Bennett, A., Goldstone, A., Hann, I., Stevens, R., Rees, J. and Gray, R. (1995). A simple robust and highly predictive prognostic index for the determination of risk directed therapy in acute myeloid leukemia (AML) derived from the United Kingdom Medical Research Council (MRC) AML 10 trial. Blood, 86, 598a (abstr, suppl. 1).
9. Martinez-Climent, J. A., Lane, N. J., Rubin, C. M., Morgan, E., Johnstone, H. S., Mick, R., Murphy, S. B., Vardiman, J. W., Larson, R. A., Le Beau, M. M. et al. (1995). Clinical and prognostic significance of chromosomal abnormalities in childhood acute myeloid leukemia de novo. Leukemia, 9, 95-101.
10. Erickson, P., Gao, J., Chang, K. S., Look, T., Whisenant, E., Raimondi, S., Lasher, R., Trujillo, J., Rowley, J. and Drabkin, H. (1992). Identification of breakpoints in t(8;21) acute myelogenous leukemia and isolation of a fusion transcript, AML/ETO, with similarity to Drosophila segmentation gene, runt. Blood, 80, 1825-1831.
11. Miyoshi, H., Kozu, T., Shimizu, K., Enomoto, K., Maseki, N., Kancko, Y., Kamada, N. and Ohki, M. (1993). The t(8:21) translocation in acute myeloid leukemia results in production of an AML1-MTG8 fusion transcript. EMBO J., 12, 2715-2721.
12. Erickson, P. F., Robinson, M., Owens, G. and Drabkin, H. A. (1994). The ETO portion of acute myeloid leukemia t(8;21) fusion transcript encodes a highly evolutionarily conserved, putative transcription factor. Cancer Res., 54, 1782-1786.
13. Kawasaki, E. S., Clark, S. S., Coyne, M. Y., Smith, S. D., Champlin, R., Witte, O. N. and McCormick, F. P. (1988). Diagnosis of chronic myeloid and acute lymphocytic leukemias by detection of leukemia-specific mRNA sequences amplified in vitro. Proc. Natl. Acad. Sci. USA, 85, 5698-5702.
14. Nucifora, G., Larson, R. A. and Rowley, J. D. (1993). Persistence of the 8;21 translocation in patients with acute myeloid leukemia type M2 in long-term remission. Blood, 82, 712-715.
15. Saunders, M. J., Tobal, K. and Liu Yin, J. A. (1994). Detection of t(8;21) by reverse transcriptase polymerase chain reaction in patients in remission of acute myeloid leukaemia type M2 after chemotherapy or bone marrow transplantation. Leuk. Res., 18, 891-895.
16. Tobal, K., Johnson, P. R., Saunders, M. J., Harrison, C. J. and Liu Yin, J. A. (1995). Detection of CBFB/MYH11 transcripts in patients with inversion and other abnormalities of chromosome 16 at presentation and remission. Br. J. Haematol., 91, 104-108.
17. Tobal, K., Saunders, M. J., Grey, M. R. and Liu Yin, J. A. (1995). Persistence of RARa-PML fusion mRNA detected by reverse transcriptase polymerase chain reaction in patients in long-term remission of acute promyelocytic leukaemia. Br. J. Haematol., 90, 615-618.
18. Shimizu, K., Miyoshi, H., Kozu, T., Nagata, J., Enomoto, K., Maseki, N., Kaneko, Y. and Ohki, M. (1992). Consistent disruption of the AML1 gene occurs within a single intron in the t(8;21) chromosome translocation. Cancer Res., 52, 6045-6948.
19. Tighe, J. E., Daga, A and Calabi, F. (1993). Translocation breakpoints are clustered on both chromosome 8 and chromosome 21 in the t(8;21) of acute myeloid leukemia. Blood, 81, 592-596.
20. Kozu, T., Miyoshi, H., Shimizu, K., Maseki, N., Kaneko, Y., Asou, H., Kamada, N. and Ohki, M. (1993). Junctions of the AML 1/MTG8(ETO) fusion are constant in t(8:21) acute myeloid leukemia detected by reverse transcription polymerase chain reaction. Blood, 82, 1270-1276.
21. Chang, K. S., Fan, Y. H., Stass, S. A., Estey, E. H., Wang, G., Trujillo, J. M., Erickson, P. and Drabkin, H. (1993). Expression of AML1-ETO fusion transcripts and detection of minimal residual disease in t(8;21)-positive acute myeloid leukemia. Oncogene. 8, 983-988.
22. Downing, J. R., Head, D. R., Curcio-Brint, A. M., Hulshof, M. G., Motroni, T A., Raimondi, S. C., Carroll, A. J., Drabkin, H. A., Willman, C., Theil, K. S. et al. (1993). An AML1/ETO fusion transcript is consistently detected by RNA-based polymerase chain reaction in acute myelogenous leukemia containing the (8;21) (q22;q22) translocation. Blood, 81, 2860-2865.
23. Maruyama, F., Yang, P., Stass, S. A., Cork, A., Freireich, E. J., Lee, M. S. and Chang, K S. (1993). Detection of the AML1/ETO fusion transcript in the t(8;21) masked translocation in acute myelogeneous leukemia. Cancer Res., 53, 4449-4451.
24. Nucifora, G., Dickstein, J. I., Torbenson, V., Roulston, D., Rowley, J. D. and Vardiman, J. W. (1994). Correlation between cell morphology and expression of the AML1/ETO chimeric transcript in patients with acute myeloid leukemia without t(8;21). Leukemia, 8, 1533-1538.
25. Zhang, T., Hillion, J., Tong, J. H., Cao, Q., Chen, S. J., Berger, R. and Chen, Z. (1994). AML-1 gene rearrangement and AML-1-ETO gene expression as molecular markers of acute myeloblastic leukemia with t(8;21). Leukemia, 8, 729-734.
26. Kusec, R., Laczika, K., Knobl, P., Friedl, J., Greinix, H., Kahls, P., Linkesch, W., Schwarzinger, I., Mitterbauer, G., Purtscher, B. et al. (1994). AML1/ETO fusion mRNA can be detected in remission blood samples of all patients with t(8;21) acute myeloid leukemia after chemotherapy or autologous bone marrow transplantation. Leukemia, 8, 735-739.
27. Guerrasio, A., Rosso, C., Martinelli, G., Lo Coco, F., Pampinella, M., Santoro, A., Lanza, C., Allione, B., Resegotti, L. and Saglio, G. (1995). Polyclonal haemopoieses associated with long-term persistence of the AML1-ETO transcript in patients with FAB M2 acute myeloid leukaemia in continuos clinical remission. Br. J. Haematol., 90, 364-368.
28. Jurlander, J., Caligiuri, M. A., Ruutu, T., Baer, M. R., Strout, M. P., Oberkircher, A. R., Hoffmann, L., Ball, E. D., Frei-Lahr, D. A., Christiansen, N. P., Block, A. M., Knuutila, S., Herzig, G. P. and Bloomfield, C. D. (1996). Persistence of the AML1/ETO fusion transcript in patients treated wilh allogeneic bone marrow transplantation for t(8;21) leukemia. Blood, 88, 2183-2191.
29. Kwong, Y. L., Chan, V., Wong, K. F. and Chan, T. K. (1995). Use of polymerase chain reaction in the detection of AML1/ETO fusion transcript in t(8;21). Cancer, 75, 821-825.
30. Satake, N., Maseki, N., Kozu, T., Sakashita, A., Kobayashi, H., Sakurai, M., Ohki, M. and Kaneko, Y. (1995). Disappearance of AMLl-MTGS(ETO) fusion transcript in acute myeloid leukaemia patients with t(8;21) in long-term remission. Br. J. Haemotol., 91, 892-898.
31. Miyamoto, T., Nagafuji, K., Akashi, K., Harada, M., Kyo, T., Akashi, T., Takenaka, K., Mizuno, S., Gondo, H., Okamura, T., Dohy, H. and Nohi, Y. (1996). Persistence of multipotent progenitors expressing AML1/ETO transcripts in long-term remission patients with t(8;21) acute myelogeneous leukemia. Blood, 87, 4789-4796.
32. Saunders, M. J., Brereton, M. L., Adams, J. A., Tobal, K. and Liu Yin, J. A. (1996). Persistence of multipotent progenitors expressing AML1/MTG8 transcripts in patients in remission of AML M2 with t(8;21). Br. J. Haematol., 93, pp. 226 (suppl.2).
33. Tighe, J. E. and Calabi, F. (1994). Alternative, out-of-frame runt/MTG8 transcripts are encoded by the derivative (8) chromosome in the t(8;21) of acute myeloid leukemia M2. Blood, 84, 2115-2121.
34. van de Locht, L. T., Smetsers, T. F., Wittebol, S., Raymakers, R. A. and Mensink, E. J. (1994). Molecular diversity in AML1/ETO fusion transcripts in patients with t(8;21) positive acute myeloid leukaemia. Leukemia, 8, 1780-1784.
35. Saunders, M. J., Tobal, K., Keeney, S. and Liu Yin, J. A. (1996). Expression of diverse AML1/MTG8 transcripts is a consistent feature in acute myeloid leukemia with t(8;21) irrespective of disease phase. Leukemia, 10, 1139-1142.
36. Tobal, K. and Yin, J. A. (1996). Monitoring of minimal residual disease by quantitative reverse transcriptase polymerase chain reaction for AML1-MTG8 transcripts in AML-M2 with t(8;21). Blood, 88, 3704-3709.
37. Newton, J., Tobal, K. and Liu Yin, J. A. (1997). Peripheral blood as well as bone marrow samples can be used for the quantitation of AML1-MTG8 transcripts to assess effectiveness of treatment and predict relapse. Br. J. Haematol., 97, pp. 3 (suppl. 1).
38. Miyamoto, T., Nagafuji, K., Harada, M., Eto, T., Fujisaki, T., Kubota, A., Akashi, K., Mizuno, S., Takenaka, K., Kanaji, T. et al. (1995). Quantitative analysis of AML1/ETO transcripts in peripheral blood stem cell harvests from patients with t(8;21) acute myelogeneous leukaemia. Br. J. Haematol., 91, 132-138.
39. Muto, A., Mori, S., Matsushita, H., Awaya, N., Ueno, H., Takayama, N., Okamoto, S., Kizaki, M. and Ikeda, Y. (1996). Serial quantification of minimal residual disease of t(8;21) acute myelogeneous leukemia with RT-competitive PCR assay. Br. J. Haematol., 95, 85-94.